Question special
Chief Resident

HFpEF is a unique and challenging set if pts which is a growing class in number. At one hand we have got for half of our HF population (HFrEF) to offer so much while at the same time the other unfortunate half (HFpEF) is begging for something with long-term benefits.
After being tested in animal studies current RCTs are in progress to test SGLT2i in HFpEF but would the peculiar mechanism of action of this medication especially favorable effects on DM, HTN, weight loss (risk factors for HFpEF) in addition to renal protective effect make us hopeful that this drug may prove to have mortality benefit even if only in a subset of HFpEF pts?
Or am I being too enthusiastic?